Tissue Inhibitor of Metalloproteinase-3

01/01/2012 - "Inhibiting matrix metalloproteinase by cell-based timp-3 gene transfer effectively treats acute and chronic ischemic cardiomyopathy."
05/01/2014 - "TIMP-3 is highly expressed in the heart and is markedly downregulated in patients with ischaemic cardiomyopathy. "
11/01/2014 - "Gel-released TIMP-1 and TIMP-3 significantly improved cardiac function and myocardial remodeling and enhanced SMA expression in the infarcted area in ischemic cardiomyopathy model rats. "
07/01/2007 - "In conclusion, chronic doxorubicin cardiomyopathy was characterized by increased MMP and decreased TIMP-3 expression. "

12/15/2006 - "Amelioration of hepatic ischemia/reperfusion injury after inhibition of TACE activity by TIMP-3 suggests that TACE inhibition may play an important role in preventing liver ischemia/reperfusion injury warranting further experimental and clinical study."
11/01/2002 - "Tissue inhibitor of metalloproteinase-3 is associated with neuronal death in reperfusion injury."
12/15/2006 - "TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats."

05/01/2011 - "TIMP-3 deficiency resulted in a fourfold increase in cardiac rupture and 50% decrease in survival after MI. "
05/01/2011 - "Treatment with cetuximab significantly decreased the incidence of cardiac rupture and improved survival post-MI in TIMP-3(-/-) mice. "
05/01/2011 - "Deficiency in TIMP-3 increases cardiac rupture and mortality post-myocardial infarction via EGFR signaling: beneficial effects of cetuximab."
05/01/2011 - "We conclude that deficiency in TIMP-3 increases cardiac rupture post-MI via EGF/epidermal growth factor receptor (EGFR) signaling which downregulates TGF-β1 expression and collagen synthesis. "
05/01/2011 - "This study investigated the role of tissue inhibitor of metalloproteinase-3 (TIMP-3)/matrix metalloproteinase (MMP)/epidermal growth factor (EGF)/transforming growth factor (TGF)-β1 pathway in infarct healing and effects of cetuximab on cardiac rupture after MI. "

07/01/2008 - "AGTR2 treatment was found to be more effective in inhibiting ovarian cancer growth than the treatment with TIMP-3 in parallel experiments. "
03/08/2007 - "Our data indicate that inactivation of TIMP-3 by somatic mutation or promoter hypermethylation is rare in ovarian cancer."
03/08/2007 - "We analyzed 65 ovarian cancers for both somatic genetic mutations and TIMP-3 promoter hypermethylation. "
03/08/2007 - "TIMP-3 has not previously been investigated for somatic mutations or promoter hypermethylation in ovarian cancer. "
03/08/2007 - "Genetic and epigenetic analysis of the TIMP-3 gene in ovarian cancer."

05/01/2014 - "Transplantation of TIMP-3 gene-transfected VSMCs was more effective in preventing progressive cardiac dysfunction, ventricular dilatation and in reducing MMP-2, MMP-9 and TNF-α levels when compared to the transplantation of untransfected VSMCs. "